J. Pharm. Pharmacogn. Res., vol. 13, no. 4, pp. 1288-1298, Jul-Aug 2025.
DOI: https://doi.org/10.56499/jppres24.2038_13.4.1288
Original Article
Influence of iodine-containing complex on the toxicity of drugs used for the treatment of acute respiratory viral diseases and influenza virus in combined application
[Influencia del complejo que contiene yodo en la toxicidad de los medicamentos utilizados para el tratamiento de enfermedades virales respiratorias agudas y del virus de la influenza en aplicación combinada]
Lyudmila Ivanova*, Ilya Korotetskiy, Bahkytzhan Kerimzhanova, Sergey Shilov, Natalya Zubenko, Tatyana Kuznetsova, Raikhan Parenova, Alexandr Ilin
JSC Scientific Center for Anti-Infectious Drugs, Almaty 050060, Kazakhstan.
*E-mail: lyudmila_69.69@mail.ru, l.ivanova@scaid.kz
Abstract
Context: One approach to assessing pharmacodynamic drug interactions is the practical application of the Chou-Talalay theory and its combination index theorem. The algorithm for studying and analysing the effects of combinations, according to Chou-Talalay, allows for the calculation of the direction and strength of pharmacodynamic interactions using the combination index (CI) values and to establish the dose reduction index (DRI) for each component of the combination. The algorithm allows for the analysis of combinations of different qualitative and quantitative compositions and calculates the result of interaction at any level of toxicological effect in laboratories engaged in drug development and research.
Aims: To evaluate the effect of FS-1 on the toxicity of rimantadine, oseltamivir, and acetylsalicylic acid (ASA) in combined in vitro experiments.
Methods: The combined cytotoxicity effect of drugs was evaluated using neutral red on MDCK cells. The type of drug interaction was determined using the principle of median-effect and CI by correlation of doses and effects, the ratio of the value of programmed cell death to the value of actual cell death using the Chou-Talalay method.
Results: It was found that the combination FS-1/rimantadine, FS-1/oseltamivir, and FS-1/ASA can significantly reduce their toxic properties. The CI of the combined use of FS-1/rimantadine was CI = 2.018; FS-1/oseltamivir CI = 13.726, and FS-1/ASA CI = 1.518.
Conclusions: The use of Chou-Talalay algorithm makes it possible to develop recommendations for the rational use and dosing of drug combinations in clinical practice, as well as to assess the prospects for the development of new combined therapeutic technologies.
Keywords: algorithm, drug toxicity; antagonism; Chou-Talalay modeling method; combined use; combination index.
Resumen
Contexto: Un enfoque para evaluar las interacciones farmacodinámicas de los fármacos es la aplicación práctica de la teoría de Chou-Talalay y su teorema del índice de combinación. El algoritmo para estudiar y analizar los efectos de las combinaciones según Chou-Talalay permite calcular la dirección y la intensidad de las interacciones farmacodinámicas mediante los valores del índice de combinación (IC) y establecer el índice de reducción de dosis (IRD) para cada componente de la combinación. El algoritmo permite analizar combinaciones de diferentes composiciones cualitativas y cuantitativas y calcula el resultado de la interacción a cualquier nivel de efecto toxicológico en laboratorios dedicados al desarrollo e investigación de fármacos.
Objetivos: Evaluar el efecto de FS-1 sobre la toxicidad de rimantadina, oseltamivir y ácido acetilsalicílico (AAS) en experimentos in vitro combinados.
Métodos: Se evaluó el efecto citotóxico combinado de los fármacos utilizando rojo neutro en células MDCK. El tipo de interacción farmacológica se determinó mediante el principio de mediana-efecto y el IC mediante la correlación de dosis y efectos, la razón entre el valor de la muerte celular programada y el valor de la muerte celular real mediante el método de Chou-Talalay.
Resultados: Se observó que la combinación de FS-1/rimantadina, FS-1/oseltamivir y FS-1/AAS puede reducir significativamente sus propiedades tóxicas. El IC del uso combinado de FS-1/rimantadina fue de 2,018; el de FS-1/oseltamivir fue de 13,726 y el de FS-1/AAS fue de 1,518.
Conclusiones: El uso del algoritmo de Chou-Talalay permite desarrollar recomendaciones para el uso racional y la dosificación de combinaciones de fármacos en la práctica clínica, así como evaluar las perspectivas de desarrollo de nuevas tecnologías terapéuticas combinadas.
Palabras Clave: algoritmo, toxicidad farmacológica; antagonismo; método de modelado de Chou-Talalay; uso combinado; índice de combinación.
Citation Format: Ivanova L, Korotetskiy I, Kerimzhanova B, Shilov S, Zubenko N, Kuznetsova T, Parenova R, Ilin A (2025) Influence of iodine-containing complex on the toxicity of drugs used for the treatment of acute respiratory viral diseases and influenza virus in combined application. J Pharm Pharmacogn Res 13(4): 1288–1298. https://doi.org/10.56499/jppres24.2038_13.4.1288
References
Adams RLP (1980) Cell Culture for Biochemists. Amsterdam: Elsevier/North-Holland Biomedical Press.
Allen DD, Caviedes R, Cárdenas A, Shimahara T, Segura-Aguilar J, Caviedes PA (2005) Cell lines as in vitro models for drug screening and toxicity studies. Drug Dev Ind Pharm 31(8): 757–768. https://doi.org/10.1080/03639040500216246
Aleksandrova OI, Okolov IN, Khorolskaya YI, Panova IE, Blinova MI (2018) Cytotoxicity evaluation using in vitro system as a criteria of rational choice of tear substitutes. [Russian]. Ophthalmol Russia 15(2): 167-175. https://doi.org/10.18008/1816-5095-2018-2-167-175
Balanaser M, Carley M, Baron R, Finnerup NB, Moore RA, Rowbotham MC, Chaparro LE, Gilron I (2023) Combination pharmacotherapy for the treatment of neuropathic pain in adults: systematic review and meta-analysis. Pain 164(2): 230–251. https://doi.org/10.1097/j.pain.0000000000002688
Batool S, Chokkakula S, Song MS (2023) Influenza treatment: Limitations of antiviral therapy and advantages of drug combination therapy. Microorganisms 11(1): 183. https://doi.org/10.3390/microorganisms11010183
Berdibay S, Ermolaev V, Paretskaya N, Sabitov A, Martirosyan KS (2017a) Structure and physical properties of new lithium- and iodine-containing adducts. 17th International Multidisciplinary Scientific GeoConference SGEM 2017. Proc SGEM 17(61): 319–330.
Berdibay S, Sabitov A, Islamov R, Tamazyan R, Paretskaya N, Tokmoldin S, Ilin A, Martirosyan K (2017b) Coordination compounds of lithium halides with certain amino acids. Bull Natl Acad Sci Repub Kazakhstan 367: 5–7.
Berdibay S, Sabitov A, Paretskaya N, Islamov R, Tamazyan R (2017c) Phenylalanine – iodine complex and its structure. Bull Natl Acad Sci Repub Kazakhstan. Physico-Mathematical Series 3(313): 5–9.
Bijnsdorp IV, Giovannetti E, Peters GJ (2011) Analysis of drug interactions. In: Cancer Cell Culture. Methods in Molecular Biology, vol. 731. Humana Press, pp. 421–434. https://doi.org/10.1007/978-1-61779-080-5_34
Burtseva EI, Shevchenko ES, Belyakova NV, Oskerko TA, Kolobukhina LV, Merkulova LN, Vartanian RV, Prilipov AG, Rotanov M, Zaplatnikov AL (2009) Monitoring the sensitivity of epidemic strains of influenza virus isolated in Russia to etiotropic chemotherapy drugs. Vopr Virusol 54(5): 24–28.
Cady SD, Schmidt-Rohr K, Wang J, Soto CS, Degrado WF, Hong M (2010) Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 463(7281): 689–692. https://doi.org/10.1038/nature08722
Carrat F, Duval X, Tubach F, Mosnier A, Van der Werf S, Tibi A, Blanchon T, Leport C, Flahault A, Mentré F (2012) Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households. Antivir Ther 17(6): 1085–1090. https://doi.org/10.3851/IMP2128
CDC (2021) Centers for Disease Control and Prevention. https://archive.cdc.gov/www_cdc_gov/flu/about/burden/2019-2020/archive-09292021.html [Consulted 25 February 2024].
Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3): 621–681. https://doi.org/10.1124/pr.58.3.10
Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2): 440–446. https://doi.org/10.1158/0008-5472.can-09-1947
Chou TC, Chou JH, Rideout DC (1991) Quantization of synergism and antagonism of two or more drugs by computerized analysis. In: Chou TC, Rideout DC (eds.), Synergism and Antagonism in Chemotherapy. Academic Press, pp. 223–244.
Danchenko EO (2012) Evaluation of cytotoxicity of pharmaceutical substances using cell cultures. Immunopathol Allergol Infectol 2: 22–31.
De Clercq E (2019) Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5(12): 1015–1025. https://doi.org/10.1038/nrd2175
Droganov M (2004) Cell culture. Theory and Techniques. Plovdiv, Bulgaria: VAP, 285 pp.
Duarte D, Vale N (2022) Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr Res Pharmacol Drug Discov 3: 100110. https://doi.org/10.1016/j.crphar.2022.100110
Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, Tibi A, Enouf V, Charlois-Ou C, Vincent C, Andreoletti L, Tubach F, Lina B, Mentre F, Leport C (2010) Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: A randomized placebo-controlled trial. PLoS Med 7(12): 1000362. https://doi.org/10.1371/journal.pmed.1000362
Eccles R (2009) Mechanisms of symptoms of common cold and flu. Common Cold 10: 23–45. https://doi.org/10.1007/978-3-7643-9912-2_2
Eropkin MJ, Eropkina EM (2003) The cell cultures as a model system toxicity studies and screening of cytoprotective drugs. [Russian]. St. Petersburg, Russia: Morsar AV, pp. 1–36.
Eropkin MJ, Eropkina EM, Smirnova TD, Litvinova OM, Kiselev OI (2012) In vitro studies of combined drug toxicity are important for understanding how drugs interact with each other and how this affects their toxicity and efficacy. St. Petersburg, Russia: Morsar AV, pp. 1–23.
Fang HB, Chen X, Pei XY, Grant S, Tan M (2015) Experimental design and statistical analysis for three-drug combination studies. Stat Methods Med Res 26(3): 1261–1280. https://doi.org/10.1177/0962280215574320
Fischer W, Hayden F (2008) Chapter 18. Antivirals for influenza: novel agents and approaches. In: Georgiev V, Western K, McGowan J (eds): National Institute of Allergy and Infectious Diseases, NIH. Totowa, NJ: Frontiers in Research Humana Press, pp. 179–192. https://doi.org/10.1007/978-1-59745-569-5_19
Freshney RI (2005) Culture of Animal Cells: A Manual of Basic Technique (5ª ed.). Hoboken, NJ: John Wiley & Sons.
Freund B, Gravenstein S, Elliott M, Miller I (1999) Zanamivir - a review of clinical safety. Drug Suf 21(4): 267–281. https://doi.org/10.2165/00002018-199921040-00003
Galabov AS, Simeonova L, Gegova G (2006) Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antivir Chem Chemother 17(5): 251–259. https://doi.org/10.1177/095632020601700502
Gomez-Gutierrez JG, Bhutiani N, McNally MW, Chuong P, Yin W, Jones MA, Zeiderman MR, Grizzle WE, McNally LR (2021) The neutral red assay can be used to evaluate cell viability during autophagy or in an acidic microenvironment in vitro. Biotech Histochem 96(4): 302–310. https://doi.org/10.1080/10520295.2020.1802065
Ghlichloo I, Gerriets V (2023) Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK547742/
Guerrero-Garcia C, Rubio-Guerra AF (2018) Combination therapy in the treatment of hypertension. Drugs Context 7: 212531. https://doi.org/10.7573/dic.212531
Han K, Cao P, Wang Y, Xie F, Ma J, Yu M, Wang J, Xu Y, Zhang Y, Wan J (2022) A review of approaches for predicting drug-drug interactions based on machine learning. Front Pharmacol 12: 814858. https://doi.org/10.3389/fphar.2021.814858
Hay AJ (1996) Amantadine and rimantadine-mechanisms. In: Richman DD (ed.), Antiviral Drug Resistance. Chichester, UK: John Wiley & Sons Ltd., pp. 43–58.
Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliot MJ, Hammond JM, Sharp SJ, Ossi MJ; Zanamivir Family Study Group (2000) Inhaled zanamivir for prevention of influenza in families. N Eng J Med 343(18): 1282–1289. https://doi.org/10.1056/nejm200011023431801
Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O, Wightman K (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 337(13): 874–879. https://doi.org/10.1056/NEJM199709253371302
Henssler J, Alexander D, Schwarzer G, Bschor T, Baethge C (2022) Combining antidepressants vs antidepressant monotherapy for treatment of patients with acute depression: A systematic review and meta-analysis. JAMA Psychiatry 79(4): 300–312. https://doi.org/10.1001/jamapsychiatry.2021.4313
Huang H, Fang HB, Tan MT (2017) Experimental design for multi-drug combination studies using signaling networks. Biometrics 74(2) 538–547. https://doi.org/10.1111/biom.12777
Ilyicheva TN, Netesov SV, Gureyev VN (2022) COVID-19, influenza, and other acute respiratory viral infections: Etiology, immunopathogenesis, diagnosis, and treatment. Part I. COVID-19 and influenza. Mol Gen Microbiol Virol 37(1): 1-9. https://doi.org/10.3103/S0891416822010025
Ilyin AI, Kulmanov ME (2014) Pat. No. 28746. Antibacterial agent for the treatment of infectious diseases of bacterial origin and a method for its preparation. (Republic of Kazakhstan); registered in the State Register of Inventions of the Republic of Kazakhstan.
Jones JC, Yen HL, Adams P, Armstrong K, Govorkova EA (2022) Influenza antivirals and their role in pandemic preparedness. Antiviral Res 210: 105499. https://doi.org/10.1016/j.antiviral.2022.105499
Kovalskaya GN, Zhukova DY, Mikhalevich EN (2018) Interaction of drugs for injection and infusion. Siberian Medical Review 6: 12–21. https://doi.org/10.20333/2500136-2018-6-12-21
Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, Palese P, Shaw ML, Treanor J, Webster RG, García-Sastre A (2018) Influenza. Nat Rev Dis Primers 4(1): 3. https://doi.org/10.1038/s41572-018-0002-y
Kumar B, Asha K, Khanna M, Ronsard L, Meseko CA, Sanicas M (2018) The emerging influenza virus threat: status and new prospects for its therapy and control. Arch Virol 163(4): 831–844 https://doi.org/10.1007/s00705-018-3708-y
Loregian A, Mercorelli B, Nannetti G, Compagnin C, Palù G (2014) Antiviral strategies against influenza virus: towards new therapeutic approaches. Cell Mol Life Sci 71(19): 3659–3683. https://doi.org/10.1007/s00018-014-1615-2
Low ZY, Wong KH, Wen Yip AJ, Choo WS (2023). The convergent evolution of influenza A virus: Implications, therapeutic strategies and what we need to know. Curr Res Microb Sci 5: 100202. https://doi.org/10.1016/j.crmicr.2023.100202
Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, Green DV, Hertzberg RP, Janzen WP, Paslay JW, Schopfer U, Sittampalam GS (2011) Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 10(3): 188–195. https://doi.org/10.1038/nrd3368
Mahto SK, Chandra P, Rhee SW (2010) In vitro models, endpoints and assessment methods for the measurement of cytotoxicity. Toxicol Environ Health Sci 2: 87–93. https://doi.org/10.1007/BF03216487
Martsevich SY, Lukina YV, Drapkina OM (2021) Basic principles of combination drug therapy – focus on drug-drug interactions. [Russian]. Cardiovasc Ther Prevent 20(7): 3031. https://doi.org/10.15829/1728-8800-2021-3031
Matveyenko AV, Zamoshchina TA, Vaizova OY, Smagina MI, Meleshko MV, Yakimova TV (2013) Clinical Pharmacology (Pharmacotherapy): Textbook. [Russian]. Siberian State Medical University (SibGMU), p. 195.
McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M, Hayden F, Zambon M (2003) Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 47(7): 2264–2272. https://doi.org/10.1128/aac.47.7.2264-2272.2003
Mikhailov MV (1983) Clinical pharmacology. Moscow, Russia: Medicine.
National Institute of Environmental Health Sciences (2001) Guidance Document on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity. NIH Publication No. 01-4500. Research Triangle Park, NC: U.S. Department of Health and Human Services.
Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, Faix DJ, Blair PJ, de Jong MD, Prichard MN, Went GT (2010) Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 5(2): e9332. https://doi.org/10.1371/journal.pone.0009332
Novikova AV, Pozhilova EV, Novikov VE (2018) Drug interactions in the structure of complications of pharmacotherapy. [Russian]. Smol Med Alm 3: 15–17.
Ong AK, Hayden FG (2007) John F. Ender’s lecture 2006: Antivirals for influenza. J Infect Dis 196(2): 181–190. https://doi.org/10.1086/518939
Palleria C, Di Paolo A, Giofrè C, Caglioti C, Leuzzi G, Siniscalchi A, De Sarro G, Gallelli L (2013) Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci 18(7): 601–610. https://pmc.ncbi.nlm.nih.gov/articles/PMC3897029/
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2006) UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 25(13): 1605–1612. https://doi.org/10.1002/jcc.20084
Saladino R, Barontini M, Crucianelli M, Nencioni L, Sgarbanti R, Palamara AT (2010) Current advances in anti-influenza therapy. Curr Med Chem 17(20): 2101–2140. https://doi.org/10.2174/092986710791299957
Savenkova MS, Savenkov MP, Afanasyeva AA, Abramova NA (2014) Effects of antiviral and immunomodulating treatment of influenza, other acute respiratory viral infections and herpes virus infection. [Russian]. Pulmonology 5: 83–93.
Shikh EV, Ismagilov AD, Sizov ZM, Demidova OA (2017) Safety of combination pharmacotherapy in elderly patients. [Russian]. Vestn Nauch Tsentr Ekspert Med Prodk 7(1): 47–54.
Shyr ZA, Cheng YS, Lo DC, Zheng W (2021) Drug combination therapy for emerging viral diseases. Drug Discov Today 26(10) 2367–2376. https://doi.org/10.1016/j.drudis.2021.05.008
Siedentop B, Kachalov VN, Witzany C, Egger M, Kouyos RD, Bonhoeffer S (2024) The effect of combining antibiotics on resistance: A systematic review and meta-analysis. eLife 13: RP93740. https://doi.org/10.7554/eLife.93740.3
Simeonova L, Gegova G, Galabov AS (2012) Prophylactic and therapeutic combination effects of rimantadine and oseltamivir against influenza virus A (H3N2) infection in mice. Antiviral Res 95(2): 172–181. https://doi.org/10.1016/j.antiviral.2012.05.004
Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD (2009) Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother 53(5): 2120–2128. https://doi.org/10.1128/aac.01012-08
Stielow M, Witczyńska A, Kubryń N, Fijałkowski Ł, Nowaczyk J, Nowaczyk A (2023) The bioavailability of drugs - The current state of knowledge. Molecules 28(24): 8038–8057. https://doi.org/10.3390/molecules28248038
Strachunsky LS, Belousova YB, Kozlova SN (2007) Anti-influenza chemotherapy drugs: A practical guide to anti-infective chemotherapy. [Russian]. Smolensk: Makmakh.
Sullivan GJ, Delgado NN, Maharjan R, Cain AK (2020) How antibiotics work together: molecular mechanisms behind combination therapy. Curr Opin Microbiol 57: 31–40. https://doi.org/10.1016/j.mib.2020.05.012
Sun W, Sanderson PE, Zheng W (2016) Drug combination therapy increases successful drug repositioning. Drug Discov Today 21(7): 1189–1195. https://doi.org/10.1016/j.drudis.2016.05.015
Świerczyńska M, Mirowska-Guzel DM, Pindelska E (2022) Antiviral drugs in influenza. Int J Environ Res Public Health 19(5): 3018. https://doi.org/10.3390/ijerph19053018
Szymański P, Markowicz M, Mikiciuk-Olasik E (2012) Adaptation of high-throughput screening in drug discovery-toxicological screening tests. Int J Mol Sci 13(1): 427–452. https://doi.org/10.3390/ijms13010427
Thompson WW, Weintraub E, Dhankhar P, Cheng PY, Brammer L, Meltzer MI, Bresee JS, Shay DK (2009) Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respir Viruses 3(1): 37–49. https://doi.org/10.1111/j.1750-2659.2009.00073.x
Turganbay S, Sabitov AN, Liu M, Zhumabaev MR, Kasimbekova SS (2021) Study of the distribution of the coordinating compound. C11H12N2O2•(C11H13N2O2)+•NA+•2Н2О•(I4)2- in mice organism by radioisotope method. Int J Biol Chem 14(1): 96–105. https://doi.org/10.26577/ijbch.2021.v14.i1.010
Wakuri S, Izumi J, Sasaki K, Tanaka N, Ono H (1993) Cytotoxicity study of 32 MEIC chemicals by colony formation and ATP assays. Toxicol In Vitro 7(4): 517–521. https://doi.org/10.1016/0887-2333(93)90057-c
Wathen MW, Barro M, Bright RA (2012) Antivirals in seasonal and pandemic influenza--future perspectives. Influenza Other Respir Viruses 7(suppl 1): 76–80. https://doi.org/10.1111/irv.12049
Yuldasheva GA, Kurmanaliyeva A, Ilin A (2021) Structure of the active nanocomplex of antiviral and anti-infectious iodine-containing drug FS-1. Quantum Rep 3(4): 746–812. https://doi.org/10.3390/quantum3040047
Yuldasheva GA, Zhidomirov GM, Ilin AI (2014) The antitumor activity of molecular iodine complexes with lithium halogenides and bioorganic ligands when applied in combination with doxorubicin. J Antivir Antiretrovir 6(2): 50–53. https://doi.org/10.4172/jaa.1000096
Yusuf S, Attaran A, Bosch J, Joseph P, Lonn E, McCready T, Mente A, Nieuwlaat R, Pais P, Rodgers A, Schwalm JD, Smith R, Teo K, Xavier D; Working Group on the Summit on Combination Therapy for CVD (2014) Combination pharmacotherapy to prevent cardiovascular disease: Present status and challenges. Eur Heart J 35(3): 353–364. https://doi.org/10.1093/eurheartj/eht407
© 2025 Journal of Pharmacy & Pharmacognosy Research